Patent application title: Methods and assays for treating conditions in which macrophages play a pathogenic role
Dianne Cox (New Rochelle, NY, US)
IPC8 Class: AA61K3800FI
Class name: Designated organic active ingredient containing (doai) peptide (e.g., protein, etc.) containing doai arteriosclerosis (e.g., atherosclerosis, etc.) affecting
Publication date: 2012-03-29
Patent application number: 20120077734
Methods and assays are disclosed for treating a subject with a disease or
condition in which macrophages play a pathogenic role using agents that
inhibit or down regulate Wiskott-Aldrich syndrome protein (WASP).
1. A method for treating a subject with a disease or condition in which
macrophages play a pathogenic role comprising administering to the
subject an agent that inhibits Wiskott-Aldrich syndrome protein (WASP) or
down regulates expression of Wiskott-Aldrich syndrome protein (WASP).
2. The method of claim 1, wherein the disease or condition is cancer, chronic inflammatory disease, arthritis, atherosclerosis or osteoporosis.
3. The method of claim 1, wherein the disease is prostate, pancreas, colon, brain, liver, lung, head, neck or breast cancer.
4. The method of claim 1, wherein the disease is cancer and wherein the agent inhibits tumor cell invasiveness, inhibits tumor cell metastasis, and/or inhibits tumor vascularization.
5. The method of claim 1, wherein the agent interferes with WASP phosphorylation or blocks an interaction between WASP and a downstream effector.
6. The method of claim 1, wherein the agent does not inhibit or down regulate N-WASP.
7. A method for screening for an agent for treating a subject with a disease or condition in which macrophages play a pathogenic role, comprising determining whether or not the agent inhibits Wiskott-Aldrich syndrome protein (WASP) or down regulates expression of Wiskott-Aldrich syndrome protein (WASP), wherein an agent that inhibits Wiskott-Aldrich syndrome protein (WASP) or down regulates expression of Wiskott-Aldrich syndrome protein (WASP) is a candidate for treating a subject with a disease or condition in which macrophages play a pathogenic role.
8. The method of claim 7, comprising determining whether or not the agent inhibits or down regulates N-WASP, wherein an agent that inhibits or down regulates WASP but does not inhibit or down regulate N-WASP is a candidate for treating a subject with a disease or condition in which macrophages play a pathogenic role.
9. The method of claim 7, wherein the disease or condition is cancer, chronic inflammatory disease, arthritis, atherosclerosis or osteoporosis.
10. The method of claim 7, wherein the disease is prostate, pancreas, colon, brain, liver, lung, head, neck or breast cancer.
11. The method of claim 7, wherein the disease is cancer and wherein the agent inhibits tumor cell invasiveness, inhibits tumor cell metastasis, and/or inhibits tumor vascularization.
12. The method of claim 7, wherein the agent interferes with WASP phosphorylation or blocks an interaction between WASP and a downstream effector.
CROSS-REFERENCE TO RELATED APPLICATION
 This application claims the benefit of U.S. Provisional Patent Application No. 61/387,532, filed on Sep. 29, 2010, the content of which is herein incorporated by reference.
BACKGROUND OF THE INVENTION
 Throughout this application various publications are referred to in parenthesis. Full citations for these references may be found at the end of the specification. The disclosures of these publications are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.
 Macrophages (Mφs) are essential components of innate immunity; however, they can also pose disadvantages to the host in certain pathological conditions such as chronic inflammatory diseases or cancer. Tumor-associated macrophages (TAMs), which are present in large numbers in many tumors, appear to play an important role in promoting the progression of solid tumors to an invasive, metastatic phenotype where TAMs play multiple roles in the tumor microenvironment to support metastasis, such as proteolysis of extra-cellular matrix, angiogenesis, enhancing carcinoma cell invasion and their intravasation leading to metastasis (reviewed in (Condeelis and Pollard 2006)). However, the precise role of Mφs in each of these steps is still unknown. The actin cytoskeleton of leukocytes plays a central role in the regulation of cell shape, migration and secretion of growth factor and proteolytic enzymes. Wiskott-Aldrich syndrome protein (WASP) is an activator of the actin nucleator Arp2/3 complex in vitro and expressed exclusively in hematopoietic cells. WASP is mutated in patients with Wiskott-Aldrich syndrome, which is a X-linked genetic disease that causes cellular and humoral immunodeficiency in its complete form (Conley, Notarangelo et al. 1999), and is believed to serve as a key integrator between surface receptors and the cytoskeleton of leukocytes. Mφs from Wiskott-Aldrich syndrome patients demonstrate defects in phagocytosis, podosome mediated matrix degradation and directional migration when placed in a gradient of Mφ chemoattractants, such as colony-stimulating factor-1 (CSF-1) (reviewed in (Thrasher and Burns)). Notably, high circulating levels of CSF-1 in breast cancer patients are positively correlated with poor prognosis (Kacinski, Scata et al. 1991; Scholl, Pallud et al. 1994; Scholl, Lidereau et al. 1996) and CSF-1 deficient mice show lower rates of metastasis (Lin, Nguyen et al. 2001). Since Mφ recruitment to tumors and their motility within tumors are required to exert their pathological functions in the tumor microenvironment, WASP deficiency in Mφs may attenuate tumor invasion and metastasis.
 The present invention addresses the need for methods and assays for compounds for treating subjects with diseases and conditions in which macrophages play a pathogenic role.
SUMMARY OF THE INVENTION
 The present invention provides methods for treating a subject with a disease or condition in which macrophages play a pathogenic role comprising administering to the subject an agent that inhibits Wiskott-Aldrich syndrome protein (WASP) or down regulates expression of Wiskott-Aldrich syndrome protein (WASP).
 The present invention also provides methods for screening for agents for treating a subject with a disease or condition in which macrophages play a pathogenic role, the methods comprising determining whether or not the agent inhibits Wiskott-Aldrich syndrome protein (WASP) or down regulates expression of Wiskott-Aldrich syndrome protein (WASP), wherein an agent that inhibits Wiskott-Aldrich syndrome protein (WASP) or down regulates expression of Wiskott-Aldrich syndrome protein (WASP) is a candidate for treating a subject with a disease or condition in which macrophages play a pathogenic role.
BRIEF DESCRIPTION OF THE DRAWINGS
 FIG. 1A-1D. WASP is required for macrophage-dependent breast carcinoma cell invasion. (A) Schematic illustration of the 3D invasion assay. (B) X-Z reconstruction of confocal images of 3D invasion assay using celltracker green labeled carcinoma cells (MTLn3) cultured on their own or co-cultured with celltracker red labeled primary bone marrow derived macrophages (BMM) isolated from either wild type (WT) or WASP knockout (WASP-/-) mice. Dotted line indicates the arbitrary threshold for measuring invasion at 20 μm (˜2 cell diameter). Quantification of cell tracker dye labeled (C) macrophage and (D) MTLn3 invasion. Fluorescence from cells was recorded at 5 μm step size. Collagen invasion is plotted as fraction of cells where fluorescence intensities above 20 μm are divided by total fluorescence from the entire stack (n=3 mice per genotype, age and sex matched). Error bars signify SEM. *** p<0.001 compared to WT macrophage co-cultured conditions.
 FIG. 2A-2C. WASP is required for the secretion of the carcinoma cell chemoattractant EGF. (A) Quantification of the MTLn3 invasion by MTLn3 cells alone, in response to wildtype BMM conditioned media (WT-CM) or conditioned media from WASP deficient mice (+KO CM) p<** 0.01 ***0.001 compared to wild-type macrophage conditioned media (WT CM). (B) Quantification of the MTLn3 invasion by MTLn3 cells alone, with wildtype BMM conditioned media (WT-CM) alone or with control IgG (Ctrl IgG) or with two different neutralizing anti-EGF antibodies generated in goat or rabbit (nEGF-G or nEGF-R). (C) Quantification of the MTLn3 invasion by MTLn3 cells alone, with WASP deficient BMM conditioned media (+KO CM), or KO CM with exogenously added 25 nM EGF. n=3. Error bars signify SEM.
 FIG. 3A-3B. WASP is required for spontaneous lung metastasis (A) Average tumor volume on day of experiment from WT, WASP+/- and WASP-/- mice following MTLn3 injection into their mammary fat pads. (B) Lung metastasis was quantified by directly observing the whole lung under fluorescent microscope and counting blue fluorescent MTLn3 within. Inset of fluorescent images are an example of lung metastasis nodule (>5 cells in same location) and single cell counts. (n=5 for WT mice, 11 for WASP+/- and 9 for WASP-/- mice. Error bars signify SEM. * p<0.05 compared to WT mice. FIG. 4A-4C. WASP is required for spontaneous lung metastasis of human MDA-MD231-4173. (A) Quantification of the MTLn3 invasion by MTLn3 cells alone, in response to wildtype BMM (WT) or WASP deficient mice (WASP-/-) ** p<0.01 compared to WT. (B) Average tumor volume on day of experiment from WASP+/- and WASP-/- mice. (C) Lung metastasis was quantified by directly observing the whole lung under fluorescent microscope and counting blue fluorescent MTLn3 within of nodules (>5 cells in same location) and single cell counts. (n=3 for WASP+/- and WASP-/- mice. Error bars signify SEM. p<* 0.05 **0.01 compared to WASP+/- mice.
 FIG. 5. WASP is required for efficient macrophage infiltration of tumor in vivo. Multiphoton intravital stack images were taken from the tumor cortex. Quantification of the total number of macrophages in the field from tumor cortex to 100 μm into the tumor. n=3 independent mice.
 FIG. 6A-6B. WASP is required for macrophage dependent carcinoma cell invasion in vivo. (A) Schematic illustration of in vivo invasion assay. (B) Quantification of the number of cells collected into the needle after 4 hours with EGF or without EGF (buffer) from wildtype, WASP+/- or WASP-/- mice bearing MTLn3 tumor. Cell counting was performed single blinded where the counter was not aware of the genotype of the mice. n=4 independent WT and 4 WASp-/- mice used) Error bars signify SEM. ** p<0.01 compared to buffer and EGF needle in WASP-/- mice.
 FIG. 7. WASP enhances tumor cell motility in vivo. Multiphoton intravital stack images were collected from the tumor cortex=0 μm, where there is no tumor cell in the field to 100 μm into the tumor for 30 min. Quantification of the total number of carcinoma cells (MTLn3) moving per field. n=3 mice per genotype. * p<0.05.
 FIG. 8. WASP phosphorylation regulates the paracrine interaction of macrophages with carcinoma cells. Quantification of the MTLn3 invasion by MTLn3 cells alone or in response to control RAW264.7 macrophage (Ctrl), treated with siRNA against WASP (shWASP), shWASP cells reconstituted with Cdc42 binding deficient (H246D), phopho-mimic (Y291E), phospho-deficient (Y291F) and wildtype WASP (WT). n>3 independent experiments. Error bars signify SEM.
DETAILED DESCRIPTION OF THE INVENTION
 The present invention provides a method for treating a subject with a disease or condition in which macrophages play a pathogenic role comprising administering to the subject an agent that inhibits Wiskott-Aldrich syndrome protein (WASP) or down regulates expression of Wiskott-Aldrich syndrome protein (WASP).
 The present invention also provides a method for screening for an agent for treating a subject with a disease or condition in which macrophages play a pathogenic role, comprising determining whether or not the agent inhibits Wiskott-Aldrich syndrome protein (WASP) or down regulates expression of Wiskott-Aldrich syndrome protein (WASP), wherein an agent that inhibits Wiskott-Aldrich syndrome protein (WASP) or down regulates expression of Wiskott-Aldrich syndrome protein (WASP) is a candidate for treating a subject with a disease or condition in which macrophages play a pathogenic role.
 The disease or condition can be, for example, cancer, chronic inflammatory disease, arthritis, atherosclerosis or osteoporosis. Where the disease is cancer, inhibiting Wiskott-Aldrich syndrome protein (WASP) or down regulating expression of Wiskott-Aldrich syndrome protein (WASP) may inhibit tumor progression and/or metastasis. For example, the agent may inhibit tumor cell invasiveness, inhibit tumor cell metastasis, and/or inhibit tumor vascularization. The cancer can be, for example, a prostate, pancreas, colon, brain, liver, lung, head or neck cancer, or in particular breast cancer.
 The agent can, for example, interfere with WASP phosphorylation or block the interaction between WASP and one or more downstream effectors. Many proteins can bind to WASP and regulate its activity such as Cdc42, PIP2, Toca-1, Src family kinases, vasp, CK2, NCK, GRB, CRKL, syndapin, and PSTPIP1. The best characterized downstream effector of WASP is Arp2/3. WASP binding of the Arp2/3 complex activates Arp2/3 actin polymerization activity. WASP also binds to a number of proteins that may regulate additional activities such as vesicle trafficking.
 WASP can be inhibited using, for example, a small molecule inhibitor, small interfering RNA, small interfering RNA using shorthairpin RNA, or cell penetrating phosphopeptide or peptide to block the binding of a WASP effector to WASP. It may also be possible to inhibit WASP by inhibiting an upstream activator such as Src family kinases or Cdc42, but blocking these proteins would not only have effects on WASP activity and therefore would be less specific.
 WASP is one protein in a family called the WASP/WAVE proteins. WASP is most closely related to the ubiquitously expressed family member N-WASP and then the related WAVE family including WAVE 1, 2 and 3. In one embodiment, human WASP protein has the following amino sequence (NCBI Reference Sequence: NP--000368.1) (Derry et al. 1994) (SEQ ID NO:1):
TABLE-US-00001 1 msggpmggrp ggrgapavqq nipstllqdh enqrlfemlg rkcltlatav vqlylalppg 61 aehwtkehcg avcfvkdnpq ksyfirlygl qagrllweqe lysqlvystp tpffhtfagd 121 dcqaglnfad edeaqafral vqekiqkrnq rqsgdrrqlp ppptpaneer rgglpplplh 181 pggdqggppv gplslglatv diqnpditss ryrglpapgp spadkkrsgk kkiskadiga 241 psgfkhvshv gwdpqngfdv nnldpdlrsl fsragiseaq ltdaetskli ydfiedqggl 301 eavrqemrrq eplpppppps rggnqlprpp ivggnkgrsg plppvplgia pppptprgpp 361 ppgrggpppp pppatgrsgp lpppppgagg ppmppppppp ppppssgngp appplppalv 421 pagglapggg rgalldqirq giqlnktpga pessalqppp qsseglvgal mhvmqkrsra 481 ihssdegedq agdededdew dd
In one embodiment, human N-WASP protein has the following amino sequence (NCBI Accession No. BAA20128) (Fukuoka et al. 1997) (SEQ ID NO:2):
TABLE-US-00002 1 mssvqqqppp prrvtnvgsl lltpqenesl ftflgkkcvt mssavvqlya adrncmwskk 61 csgvaclvkd npqrshflri fdikdgkllw eqelynnfvy nsprgyfhtf agdtcqvaln 121 faneeeakkf rkavtdllgr rqrksekrrd ppngpnlpma tvdiknpeit tnrfygpqvn 181 nishtkekkk gkakkkrltk gdigtpsnfq highvgwdpn tgsdlnnldp elknlfdmcg 241 ileaqlkere tlkviydfie ktggveavkn elrrqapppp ppsrggpppp pppphssgpp 301 pppargrgap ppppsrapta appppppsrp svevpppppn rmypppppal pssapsgppp 361 pppsvlgvgp vapppppppp pppgpppppg lpsdgdhqvp ttagnkaall dqiregaqlk 421 kveqnsrpvs csgrdalldq irqgiqlksv adgqestppt paptsgivga lmevmqkrsk 481 aihssdeded eddeedfedd dewed
 The agent that inhibits or down regulates WASP can be administered to the subject in a pharmaceutical composition comprising a pharmaceutically acceptable carrier. Examples of acceptable pharmaceutical carriers include, but are not limited to, additive solution-3 (AS-3), saline, phosphate buffered saline, Ringer's solution, lactated Ringer's solution, Locke-Ringer's solution, Krebs Ringer's solution, Hartmann's balanced saline solution, and heparinized sodium citrate acid dextrose solution. The pharmaceutically acceptable carrier used can depend on the route of administration. The pharmaceutical composition can be formulated for administration by any method known in the art, including but not limited to, oral administration, parenteral administration, intravenous administration, transdermal administration, intranasal administration, and administration through an osmotic mini-pump. The compounds can be applied to the skin, for example, in compositions formulated as skin creams, or as sustained release formulations or patches.
 Agents can be tested as possible inhibitors of WASP using, for example, an in vitro actin polymerization assay, which uses purified WASP to stimulate Arp2/3 activity, or a WASP biosensor that uses intramolecular fluorescence resonance energy transfer to report WASP activation in vivo (Cammer et al. 2009). An inhibitor of N-WASP, called wiskostatin, has been developed (Peterson et al., 2004) that also inhibits WASP. However, this inhibitor lowers the intracellular levels of ATP and therefore has non-specific effects. Preferably, an inhibitor will specifically target WASP and not have an effect on N-WASP activity. Compounds that inhibit both WASP and N-WASP can be excluded, for example, by comparing the inhibitory properties on WASP and N-WASP stimulated actin polymerization in vitro or by comparing inhibition of activity using the available WASP and N-WASP biosensors (Lorenz et al., 2004). Western blotting with a WASP specific antibody can be used, for example, to determine expression level, or qRT-PCR can be used to examine message level. Blocking downstream interactions can be examined by co-immunoprecipitation experiments.
 The invention also provides an agent identified by any of the methods disclosed herein. The agent can be used, for example, to treat cancer, chronic inflammatory disease, arthritis, atherosclerosis or osteoporosis.
 This invention will be better understood from the Experimental Details, which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims that follow thereafter.
 Recent rodent studies have demonstrated the existence of a paracrine loop interaction between epidermal growth factor (EGF) secreting TAMs and CSF-1 secreting tumor cells, which promote mutual migration of both cell types leading to tumor cell invasion and metastasis (Wyckoff, Wang et al. 2004; Goswami, Sahai et al. 2005). To test whether WASP can promote carcinoma cell invasion in 3D, collagen gel matrix was layered over co-cultured WASP-deficient bone marrow derived Mφs (BMM) and highly metastatic breast tumor cells (MTLn3) (FIG. 1). Akin to results from previously published 3D invasion study using Mφ cell lines (Goswami, Sahai et al. 2005), control bone marrow-derived Mφ (BMM) significantly invaded the collagen gel, while the WASP-deficient BMM did not promote MTLn3 invasion at all (FIG. 1). Consistent with the paracrine interaction between Mφ and tumor cells, MTLn3 invasion was significantly enhanced by the presence of control BMM, while the WASP-deficient BMM did not promote MTLn3 invasion (FIG. 1D).
 Interestingly, the defect in MTLn3 invasion could be partially rescued by the addition of conditioned media from control BMM but not with conditioned media from WASP-deficient BMM (FIG. 2A). Since neutralizing antibodies against EGF attenuated the effect of conditioned media and addition of EGF to WASP deficient conditioned media restored carcinoma cell invasion, this indicated that WASP also plays a role in secretion of carcinoma cell chemoattractants (FIGS. 2B and 2C). To confirm that the effect of co-culture was in fact due to the proposed paracrine interaction, the effect of adding small molecule inhibitors of CSF-1R and EGFR were tested. The addition of either inhibitor effectively blocked the effect of co-culture (data not shown). These findings support the hypothesis that both WASP dependent secretion and macrophage migration are important in supporting the high level of carcinoma invasiveness.
 Taken together, these findings support the hypothesis that WASP plays a role in the paracrine interaction between Mφs and carcinoma cells, leading to the co-migration of both cell types required to induce the high level of carcinoma cell invasiveness observed in vitro and in vivo. Therefore, xenograft competent (Rag2-/-)/WASP-deficient mice were generated with GFP expressing Mφs (under the control of the cfms promotor), and MTLn3-CFP was injected into the mammary fat pad. Primary tumor growth rate was not significantly different between control and WASP-deficient mice (FIG. 3A). However, lungs from WASP-deficient mice contained significantly fewer metastatic cells compared to control mice, as assessed by CFP fluorescence (FIG. 3B). These results were confirmed using the highly invasive human metastatic breast cancer cell line, MDA-MB-231-4173 (Lu and Kang 2009). Correspondingly, WASP-deficient macrophages failed to promote MDA-MB-231-4173 invasion in vitro and metastasis was significantly reduced in WASp-deficient mice injected with MDA-MB-231 cells, indicating WASp plays a key role in the paracrine interaction that leads to tumor progression and metastasis using a human model system (FIG. 4).
 The presence and absence of WASP in tumors was further characterized to determine the precise defect in the absence of WASP that led to reduced metastasis. Both histological samples and intravital imaging of the fluorescent carcinoma cells and macrophages showed a small but significant reduction in the number of TAMs in tumors of WASP-deficient mice compared to control mice (FIG. 5). Carcinoma cell invasiveness in the tumor was monitored and analyzed using a well established in vivo needle invasion assay that mimics the invasion of carcinoma cells into a blood vessel, according to Wyckoff et al. (Wyckoff, Segall et al. 2000). Consistent with the block in the paracrine interaction observed in vitro in the absence of WASP, EGF significantly enhanced the number of carcinoma cells collected into a needle from tumor bearing control mice while there was no difference in the number of cells collected into needle containing buffer alone or EGF from tumor bearing WASP-deficient mice (FIG. 6). Additionally, a reduction was also observed in the motility of carcinoma cells in the tumors of WASP deficient mice as compared with control mice (FIG. 7). These data are consistent with the in vitro data and support a role for WASP in regulating the ability of TAMs to enhance carcinoma cell motilty and invasion leading to metastatic spread.
 TAMs have also been proposed to aid tumor progression by breakdown of the extracellular matrix and by promoting angiogenesis. WASP is required for the formation of podosomes, F-actin rich ventral adhesion structures of leukocytes, including Mφs dendritic cells and osteoclasts that mediate matrix degradation (reviewed in (Linder and Aepfelbacher 2003)). Consistent with a role for WASP in matrix degradation, resting or activated macrophages from WASP-deficient mice show reduced ability to degrade matrix (Isaac, Ishihara et al.). Furthermore, using a Mφ cell line in which levels of endogenous WASP has been reduced using siRNA and then reconstituted to express mutant forms of WASP, it was recently shown that phosphorylation of WASP regulates many of WASP functions such as phagocytosis, matrix degradation and chemotaxis (Dovas, Gevrey et al. 2009; Park and Cox 2009). Consistent with key role of WASP phosphorylation in Mφ function, cells that express either phospho-deficient or phospho-mimicking forms of WASP demonstrate altered carcinoma cell invasion in vitro (FIG. 8). These results suggests that regents that interfere with WASP phosphorylation or would block the interaction between WASP and downstream effectors might also be effective in inhibiting the paracrine interaction between TAMs and carcinoma cells in vivo. In addition, reduced tumor vascularization was observed in the tumors from WASP-deficient mice suggesting a role for WASP in tumor angiogenesis. CSF-1 dependent TAMs are known to promote tumor angiogeneis through the secretion of VEFG, enhancing tumor progression (Lin, Li et al. 2007; Ojalvo, King et al. 2009).
 The present data demonstrate that WASP plays a major role in macrophage-mediated tumor progression and metastasis suggesting WASP inhibition may have therapeutic benefit in the treatment of breast tumor progression.
 Breast cancer continues to be the most frequently diagnosed and second leading cause of death from cancer in women. While early detection and advent of combination therapy show an increase in mortality, the presence of metastasis generally implies poor prognosis. While chemotherapy continues to get more sophisticated and specific, frequently tumor cells develop resistance to these drugs resulting in recurrence and metastasis. Therefore, targeting an important molecule in cancer progression that is expressed in more stable, non-cancerous cells host cells is a promising addition and/or an alternative to the current therapeutic regimen since the host cells are much less likely to develop resistance. WASP may be a viable candidate since WASP is an important molecule in tumor progression and yet it is expressed exclusively in hematopoietic cells. In addition, targeted therapeutics against WASP may also be applicable to chronic inflammatory diseases where Mφs appear to play pathogenic roles such as arthritis and atherosclerosis. In addition, since this protein is important in mediating osteoclast function, this invention may also be applicable to the treatment of osteoporosis.
 Cammer M, Gevrey J C, Lorenz M, Dovas A, Condeelis J, Cox D. The mechanism of CSF-1-induced Wiskott-Aldrich syndrome protein activation in vivo: a role for phosphatidylinositol 3-kinase and Cdc42. J Biol Chem. 2009 Aug. 28; 284(35):23302-11. Epub 2009 Jun. 26.  Condeelis, J. and J. W. Pollard (2006). Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2): 263-6.  Conley, M. E., L. D. Notarangelo, et al. (1999). Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 93(3): 190-7.  Derry, J. M., Ochs, H. D. and Francke, U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 78 (4): 635-644 (1994).  Dovas, A., J. C. Gevrey, et al. (2009). Regulation of podosome dynamics by WASp phosphorylation: implication in matrix degradation and chemotaxis in macrophages. J Cell Sci 122(Pt 21): 3873-82.  Fukuoka, M., Miki, H. and Takenawa, T. Identification of N-WASP homologs in human and rat brain. Gene 196 (1-2): 43-48 (1997).  Goswami, S., E. Sahai, et al. (2005). Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 65(12): 5278-83.  Isaac, B. M., D. Ishihara, et al. N-WASP has the ability to compensate for the loss of WASP in macrophage podosome formation and chemotaxis. Exp Cell Res. 2010 Dec. 10; 316(20):3406-16. Epub 2010 Jun. 27.  Kacinski, B. M., K. A. Scata, et al. (1991). FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 6(6): 941-52.  Lorenz M, Yamaguchi H, Wang Y, Singer R H, Condeelis J (2004). "Imaging sites of N-WASP activity in lamellipodia and invadopodia of carcinoma cells." Curr Biol. 14(8):697-703.  Lin, E. Y., J. F. Li, et al. (2007). "Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages." Mol Oncol 1(3): 288-302.  Lin, E. Y., A. V. Nguyen, et al. (2001). "Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy." J Exp Med 193(6): 727-40.  Linder, S. and M. Aepfelbacher (2003). "Podosomes: adhesion hot-spots of invasive cells." Trends Cell Biol 13(7): 376-85.  Lu, X. and Y. Kang (2009). "Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants." Proc Natl Acad Sci USA 106(23): 9385-90.  Ojalvo, L. S., W. King, et al. (2009). "High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors." Am J Pathol 174(3): 1048-64.  Park, H. and D. Cox (2009). "Cdc42 regulates Fc gamma receptor-mediated phagocytosis through the activation and phosphorylation of Wiskott-Aldrich syndrome protein (WASP) and neural-WASP." Mol Biol Cell 20(21): 4500-8.  Peterson J R, Bickford L C, Morgan D, Kim A S, Ouerfelli O, Kirschner M W, Rosen M K (2004). "Chemical inhibition of N-WASP by stabilization of a native autoinhibited conformation." Nat Struct Mol Biol. 11(8):747-55.  Scholl, S. M., R. Lidereau, et al. (1996). "Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study." Breast Cancer Res Treat 39(3): 275-83.  Scholl, S. M., C. Pallud, et al. (1994). "Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis." J Natl Cancer Inst 86(2): 120-6.  Thrasher, A. J. and S. O. Burns "WASP: a key immunological multitasker." Nat Rev Immunol 10(3): 182-92.  Wyckoff, J., W. Wang, et al. (2004). "A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors." Cancer Res 64(19): 7022-9.  Wyckoff, J. B., J. E. Segall, et al. (2000). "The collection of the motile population of cells from a living tumor." Cancer Res 60(19): 5401-4.
21502PRTHomo sapiens 1Met Ser Gly Gly Pro Met Gly Gly Arg Pro Gly Gly Arg Gly Ala Pro1 5 10 15Ala Val Gln Gln Asn Ile Pro Ser Thr Leu Leu Gln Asp His Glu Asn 20 25 30Gln Arg Leu Phe Glu Met Leu Gly Arg Lys Cys Leu Thr Leu Ala Thr 35 40 45Ala Val Val Gln Leu Tyr Leu Ala Leu Pro Pro Gly Ala Glu His Trp 50 55 60Thr Lys Glu His Cys Gly Ala Val Cys Phe Val Lys Asp Asn Pro Gln65 70 75 80Lys Ser Tyr Phe Ile Arg Leu Tyr Gly Leu Gln Ala Gly Arg Leu Leu 85 90 95Trp Glu Gln Glu Leu Tyr Ser Gln Leu Val Tyr Ser Thr Pro Thr Pro 100 105 110Phe Phe His Thr Phe Ala Gly Asp Asp Cys Gln Ala Gly Leu Asn Phe 115 120 125Ala Asp Glu Asp Glu Ala Gln Ala Phe Arg Ala Leu Val Gln Glu Lys 130 135 140Ile Gln Lys Arg Asn Gln Arg Gln Ser Gly Asp Arg Arg Gln Leu Pro145 150 155 160Pro Pro Pro Thr Pro Ala Asn Glu Glu Arg Arg Gly Gly Leu Pro Pro 165 170 175Leu Pro Leu His Pro Gly Gly Asp Gln Gly Gly Pro Pro Val Gly Pro 180 185 190Leu Ser Leu Gly Leu Ala Thr Val Asp Ile Gln Asn Pro Asp Ile Thr 195 200 205Ser Ser Arg Tyr Arg Gly Leu Pro Ala Pro Gly Pro Ser Pro Ala Asp 210 215 220Lys Lys Arg Ser Gly Lys Lys Lys Ile Ser Lys Ala Asp Ile Gly Ala225 230 235 240Pro Ser Gly Phe Lys His Val Ser His Val Gly Trp Asp Pro Gln Asn 245 250 255Gly Phe Asp Val Asn Asn Leu Asp Pro Asp Leu Arg Ser Leu Phe Ser 260 265 270Arg Ala Gly Ile Ser Glu Ala Gln Leu Thr Asp Ala Glu Thr Ser Lys 275 280 285Leu Ile Tyr Asp Phe Ile Glu Asp Gln Gly Gly Leu Glu Ala Val Arg 290 295 300Gln Glu Met Arg Arg Gln Glu Pro Leu Pro Pro Pro Pro Pro Pro Ser305 310 315 320Arg Gly Gly Asn Gln Leu Pro Arg Pro Pro Ile Val Gly Gly Asn Lys 325 330 335Gly Arg Ser Gly Pro Leu Pro Pro Val Pro Leu Gly Ile Ala Pro Pro 340 345 350Pro Pro Thr Pro Arg Gly Pro Pro Pro Pro Gly Arg Gly Gly Pro Pro 355 360 365Pro Pro Pro Pro Pro Ala Thr Gly Arg Ser Gly Pro Leu Pro Pro Pro 370 375 380Pro Pro Gly Ala Gly Gly Pro Pro Met Pro Pro Pro Pro Pro Pro Pro385 390 395 400Pro Pro Pro Pro Ser Ser Gly Asn Gly Pro Ala Pro Pro Pro Leu Pro 405 410 415Pro Ala Leu Val Pro Ala Gly Gly Leu Ala Pro Gly Gly Gly Arg Gly 420 425 430Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Asn Lys Thr Pro 435 440 445Gly Ala Pro Glu Ser Ser Ala Leu Gln Pro Pro Pro Gln Ser Ser Glu 450 455 460Gly Leu Val Gly Ala Leu Met His Val Met Gln Lys Arg Ser Arg Ala465 470 475 480Ile His Ser Ser Asp Glu Gly Glu Asp Gln Ala Gly Asp Glu Asp Glu 485 490 495Asp Asp Glu Trp Asp Asp 5002505PRTHomo sapiens 2Met Ser Ser Val Gln Gln Gln Pro Pro Pro Pro Arg Arg Val Thr Asn1 5 10 15Val Gly Ser Leu Leu Leu Thr Pro Gln Glu Asn Glu Ser Leu Phe Thr 20 25 30Phe Leu Gly Lys Lys Cys Val Thr Met Ser Ser Ala Val Val Gln Leu 35 40 45Tyr Ala Ala Asp Arg Asn Cys Met Trp Ser Lys Lys Cys Ser Gly Val 50 55 60Ala Cys Leu Val Lys Asp Asn Pro Gln Arg Ser His Phe Leu Arg Ile65 70 75 80Phe Asp Ile Lys Asp Gly Lys Leu Leu Trp Glu Gln Glu Leu Tyr Asn 85 90 95Asn Phe Val Tyr Asn Ser Pro Arg Gly Tyr Phe His Thr Phe Ala Gly 100 105 110Asp Thr Cys Gln Val Ala Leu Asn Phe Ala Asn Glu Glu Glu Ala Lys 115 120 125Lys Phe Arg Lys Ala Val Thr Asp Leu Leu Gly Arg Arg Gln Arg Lys 130 135 140Ser Glu Lys Arg Arg Asp Pro Pro Asn Gly Pro Asn Leu Pro Met Ala145 150 155 160Thr Val Asp Ile Lys Asn Pro Glu Ile Thr Thr Asn Arg Phe Tyr Gly 165 170 175Pro Gln Val Asn Asn Ile Ser His Thr Lys Glu Lys Lys Lys Gly Lys 180 185 190Ala Lys Lys Lys Arg Leu Thr Lys Gly Asp Ile Gly Thr Pro Ser Asn 195 200 205Phe Gln His Ile Gly His Val Gly Trp Asp Pro Asn Thr Gly Ser Asp 210 215 220Leu Asn Asn Leu Asp Pro Glu Leu Lys Asn Leu Phe Asp Met Cys Gly225 230 235 240Ile Leu Glu Ala Gln Leu Lys Glu Arg Glu Thr Leu Lys Val Ile Tyr 245 250 255Asp Phe Ile Glu Lys Thr Gly Gly Val Glu Ala Val Lys Asn Glu Leu 260 265 270Arg Arg Gln Ala Pro Pro Pro Pro Pro Pro Ser Arg Gly Gly Pro Pro 275 280 285Pro Pro Pro Pro Pro Pro His Ser Ser Gly Pro Pro Pro Pro Pro Ala 290 295 300Arg Gly Arg Gly Ala Pro Pro Pro Pro Pro Ser Arg Ala Pro Thr Ala305 310 315 320Ala Pro Pro Pro Pro Pro Pro Ser Arg Pro Ser Val Glu Val Pro Pro 325 330 335Pro Pro Pro Asn Arg Met Tyr Pro Pro Pro Pro Pro Ala Leu Pro Ser 340 345 350Ser Ala Pro Ser Gly Pro Pro Pro Pro Pro Pro Ser Val Leu Gly Val 355 360 365Gly Pro Val Ala Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Gly 370 375 380Pro Pro Pro Pro Pro Gly Leu Pro Ser Asp Gly Asp His Gln Val Pro385 390 395 400Thr Thr Ala Gly Asn Lys Ala Ala Leu Leu Asp Gln Ile Arg Glu Gly 405 410 415Ala Gln Leu Lys Lys Val Glu Gln Asn Ser Arg Pro Val Ser Cys Ser 420 425 430Gly Arg Asp Ala Leu Leu Asp Gln Ile Arg Gln Gly Ile Gln Leu Lys 435 440 445Ser Val Ala Asp Gly Gln Glu Ser Thr Pro Pro Thr Pro Ala Pro Thr 450 455 460Ser Gly Ile Val Gly Ala Leu Met Glu Val Met Gln Lys Arg Ser Lys465 470 475 480Ala Ile His Ser Ser Asp Glu Asp Glu Asp Glu Asp Asp Glu Glu Asp 485 490 495Phe Glu Asp Asp Asp Glu Trp Glu Asp 500 505
Patent applications in class Arteriosclerosis (e.g., atherosclerosis, etc.) affecting
Patent applications in all subclasses Arteriosclerosis (e.g., atherosclerosis, etc.) affecting